S. 4355 · 119th Congress · Health
Drug Deal Disclosure Act
- IntroducedApr 21, 2026 Done
- CommitteeReferred to Health, Education, Labor, and Pensions Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.Who lobbies on it
1 organization · 2 filings · Q2 2026–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
America's Health Insurance Plans Inc (ahip)
2 of 2 quarters
“…S. 4355 - Drug Deal Disclosure Act - Sen. Wyden, Ron - Federal MFN agreement transparency S. 4509 - PBM Act - Sen. Warren, Elizabeth - PBM ownership requirements S. 5059 - A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products. - Sen. Moody, Ashley - Biosimilar and…”
$11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
Organizations that named S. 4355 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Apr 21, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Apr 21, 2026Introduced in Senate